$ENTA
ENANTA PHARMACEUTICALS INC

2017 Q2 Form 10-Q Financial Statement

#000156459017010224 Filed on May 10, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $7.511M $8.959M $13.00M
YoY Change -46.27% -31.11% -77.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.230M $5.460M $4.430M
YoY Change 22.2% 23.25% 28.78%
% of Gross Profit
Research & Development $15.41M $13.00M $9.143M
YoY Change 42.88% 42.23% 70.32%
% of Gross Profit
Depreciation & Amortization $550.0K $530.0K $430.0K
YoY Change 25.0% 23.26% 207.14%
% of Gross Profit
Operating Expenses $20.64M $13.00M $9.143M
YoY Change 91.38% 42.23% 70.32%
Operating Profit -$9.506M -$565.0K
YoY Change 1582.48% -101.16%
Interest Expense $600.0K $8.000K $11.00K
YoY Change 5354.55% -27.27% 450.0%
% of Operating Profit
Other Income/Expense, Net $600.0K $549.0K $472.0K
YoY Change 34.23% 16.31% 124.76%
Pretax Income -$12.53M -$8.957M -$93.00K
YoY Change 1851.71% 9531.18% -100.19%
Income Tax $4.103M $3.565M -$1.552M
% Of Pretax Income
Net Earnings -$8.426M -$5.392M -$1.645M
YoY Change 683.09% 227.78% -105.72%
Net Earnings / Revenue -112.18% -60.19% -12.65%
Basic Earnings Per Share -$0.44 -$0.28 -$0.09
Diluted Earnings Per Share -$0.44 -$0.28 -$0.09
COMMON SHARES
Basic Shares Outstanding 19.08M 19.05M 18.92M
Diluted Shares Outstanding 19.05M 18.92M

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $192.0M $175.6M $220.4M
YoY Change -12.13% -20.33% 33.17%
Cash & Equivalents $22.26M $19.21M $56.36M
Short-Term Investments $169.8M $156.4M $164.1M
Other Short-Term Assets $6.600M $6.100M $9.300M
YoY Change -29.03% -34.41% 151.35%
Inventory
Prepaid Expenses
Receivables $7.500M $8.959M $13.00M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $206.1M $190.6M $242.7M
YoY Change -14.76% -21.46% 36.49%
LONG-TERM ASSETS
Property, Plant & Equipment $8.100M $8.526M $7.691M
YoY Change 8.01% 10.86% 235.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $43.30M $65.30M $25.20M
YoY Change 65.27% 159.13% -58.89%
Other Assets $18.30M $14.50M $6.000M
YoY Change 181.54% 141.67% 33.33%
Total Long-Term Assets $69.70M $88.37M $38.93M
YoY Change 73.62% 126.99% -42.83%
TOTAL ASSETS
Total Short-Term Assets $206.1M $190.6M $242.7M
Total Long-Term Assets $69.70M $88.37M $38.93M
Total Assets $275.8M $279.0M $281.6M
YoY Change -2.18% -0.94% 14.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.500M $4.056M $2.572M
YoY Change 169.08% 57.7% 9.77%
Accrued Expenses $5.600M $5.098M $2.632M
YoY Change 22.19% 93.69% -9.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0%
Total Short-Term Liabilities $11.10M $9.154M $11.99M
YoY Change 16.0% -23.64% -39.42%
LONG-TERM LIABILITIES
Long-Term Debt $600.0K $600.0K $700.0K
YoY Change 0.0% -14.29% 250.0%
Other Long-Term Liabilities $3.300M $2.355M $1.813M
YoY Change 68.11% 29.9% 619.44%
Total Long-Term Liabilities $3.900M $2.355M $1.813M
YoY Change 98.68% 29.9% 619.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.10M $9.154M $11.99M
Total Long-Term Liabilities $3.900M $2.355M $1.813M
Total Liabilities $15.00M $12.95M $15.18M
YoY Change 16.04% -14.71% -29.95%
SHAREHOLDERS EQUITY
Retained Earnings $17.27M $30.52M
YoY Change -43.41% -1456.62%
Common Stock $248.8M $235.7M
YoY Change 5.58% 4.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $260.9M $266.0M $266.4M
YoY Change
Total Liabilities & Shareholders Equity $275.8M $279.0M $281.6M
YoY Change -2.18% -0.94% 14.52%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$8.426M -$5.392M -$1.645M
YoY Change 683.09% 227.78% -105.72%
Depreciation, Depletion And Amortization $550.0K $530.0K $430.0K
YoY Change 25.0% 23.26% 207.14%
Cash From Operating Activities -$4.790M -$3.010M $10.06M
YoY Change 127.01% -129.92% -89.82%
INVESTING ACTIVITIES
Capital Expenditures -$740.0K -$580.0K -$1.510M
YoY Change 21.31% -61.59% 1410.0%
Acquisitions
YoY Change
Other Investing Activities $8.400M $2.380M $1.060M
YoY Change -127.26% 124.53% -100.99%
Cash From Investing Activities $7.660M $1.800M -$460.0K
YoY Change -124.37% -491.3% -99.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 190.0K -210.0K 530.0K
YoY Change -90.31% -139.62% 112.0%
NET CHANGE
Cash From Operating Activities -4.790M -3.010M 10.06M
Cash From Investing Activities 7.660M 1.800M -460.0K
Cash From Financing Activities 190.0K -210.0K 530.0K
Net Change In Cash 3.060M -1.420M 10.13M
YoY Change -109.69% -114.02% -220.88%
FREE CASH FLOW
Cash From Operating Activities -$4.790M -$3.010M $10.06M
Capital Expenditures -$740.0K -$580.0K -$1.510M
Free Cash Flow -$4.050M -$2.430M $11.57M
YoY Change 170.0% -121.0% -88.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6059000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
190591000
CY2016Q3 us-gaap Assets Current
AssetsCurrent
232156000
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8526000
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8004000
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19083511
CY2017Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8959000
CY2017Q1 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
65330000
CY2016Q3 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
32119000
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
608000
CY2016Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
608000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
549000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
472000
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Revenues
Revenues
61449000
CY2017Q1 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
13903000
CY2017Q1 us-gaap Assets
Assets
278958000
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
242081000
us-gaap Revenues
Revenues
19376000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25530000
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
18465000
CY2017Q1 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-15000
us-gaap Royalty Revenue
RoyaltyRevenue
30873000
CY2017Q1 us-gaap Revenues
Revenues
8959000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
135000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19211000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16577000
CY2017Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
156362000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16552000
us-gaap Operating Income Loss
OperatingIncomeLoss
35029000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18176000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10398000
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
248654000
CY2016Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12841000
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7889000
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
269936000
CY2016Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9231000
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
281277000
CY2016Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1251000
CY2017Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2355000
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4056000
CY2017Q1 us-gaap Liabilities
Liabilities
12947000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4426000
CY2016Q3 us-gaap Liabilities
Liabilities
11341000
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19036000
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19036000
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
190000
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5098000
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
278958000
CY2016Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4512000
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
19000
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19054000
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
266011000
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19054000
CY2017Q1 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
162000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13004000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9143000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5461000
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
191000
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-108000
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
17274000
CY2016Q3 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
8390000
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
27646000
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3377000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q3 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
159000
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-1645000
us-gaap Net Income Loss
NetIncomeLoss
-10372000
CY2016Q3 us-gaap Assets
Assets
281277000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-565000
CY2016Q1 us-gaap Costs And Expenses
CostsAndExpenses
13569000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9506000
CY2016Q1 us-gaap Royalty Revenue
RoyaltyRevenue
13004000
us-gaap Royalty Revenue
RoyaltyRevenue
19376000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8957000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-93000
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19042000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1552000
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19047000
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1073000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15479000
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3565000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5107000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5392000
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19047000
CY2016Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18921000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18921000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
168000
CY2016Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
193507000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9154000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18848000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-76000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19042000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19225000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10499000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
24712000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2017Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1276000
CY2017Q1 us-gaap Royalty Revenue
RoyaltyRevenue
8959000
us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
30000000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
576000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
390000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-127000
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
572000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
408000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1121000
us-gaap Investment Income Interest
InvestmentIncomeInterest
764000
CY2017Q1 us-gaap Interest Expense
InterestExpense
8000
CY2016Q1 us-gaap Interest Expense
InterestExpense
11000
us-gaap Interest Expense
InterestExpense
20000
us-gaap Interest Expense
InterestExpense
23000
CY2016Q1 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
75000
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
60000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
801000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
35830000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11286000
us-gaap Net Income Loss
NetIncomeLoss
24544000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.28
CY2017Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-23000
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
390000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-127000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
168000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5415000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1255000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-13000
us-gaap Share Based Compensation
ShareBasedCompensation
6759000
us-gaap Share Based Compensation
ShareBasedCompensation
4374000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1021000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
772000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-5437000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-719000
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
48000
enta Premium On Marketable Securities
PremiumOnMarketableSecurities
857000
enta Premium On Marketable Securities
PremiumOnMarketableSecurities
166000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-406000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1010000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3882000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2285000
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-433000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3114000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-609000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
688000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1160000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
562000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-330000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
6048000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
349000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
135000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
143000
us-gaap Income Taxes Paid
IncomeTaxesPaid
5711000
CY2016Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2042000
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q1 us-gaap Revenues
Revenues
13004000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8244000
us-gaap Costs And Expenses
CostsAndExpenses
35928000
us-gaap Costs And Expenses
CostsAndExpenses
26420000
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
40047000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1531000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3710000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5020000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
150455000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
82182000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6089000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
661000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
33000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
202000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
48000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
676000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2634000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
34634000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56360000
CY2016Q3 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
441000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
320000
CY2016Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
745000
CY2016Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
240921000
CY2016Q3 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
696000
CY2016Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
458000
CY2016Q3 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
143000
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-28000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
151273000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
84561000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2671000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
58000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
36000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-180000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21726000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1022000
CY2017Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
234569000
CY2017Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1438000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, <font style="Background-color:#FFFFFF;">management&#8217;s judgments of separate units of accounting and best estimate of selling price of those units of accounting within its revenue arrangements; valuation of warrants, Series&#160;1 nonconvertible preferred stock and stock-based awards; and the accounting for income taxes, including uncertain tax positions and the valuation of net deferred tax assets.&#160;</font>Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#8217;s estimates.</p></div>
CY2017Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
12877000
CY2016Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
15295000
CY2016Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1410000
enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2017Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
221865000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
42000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
215000
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
221692000
CY2016Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
225596000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
80000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
50000
CY2016Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
225626000
CY2017Q1 enta Accrued Preclinical And Clinical Expenses Current
AccruedPreclinicalAndClinicalExpensesCurrent
2516000
CY2016Q3 enta Accrued Preclinical And Clinical Expenses Current
AccruedPreclinicalAndClinicalExpensesCurrent
899000
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1181000
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2384000
CY2017Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
463000
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
393000
CY2017Q1 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
312000
CY2017Q1 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
75000
CY2016Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
73000
CY2017Q1 enta Accrued Fixed Assets Purchases
AccruedFixedAssetsPurchases
47000
CY2016Q3 enta Accrued Fixed Assets Purchases
AccruedFixedAssetsPurchases
2000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
504000
CY2017Q1 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
1066000
CY2017Q1 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
706000
CY2017Q1 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
421000
CY2017Q1 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
162000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1895456
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
541619
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5857
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
105596
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2325622
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2307633
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1160475
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.75
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
29.97
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.82
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
18.35
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
29.55
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
29.54
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
26.96
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7369000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9469000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
9446000
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8015000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3492000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2382000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6759000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4374000
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
29718000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
377000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2529000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1664000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2552000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1185000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.330
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.315
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2017Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1066000
CY2016Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
745000
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-09-30
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1013000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1013000
CY2017Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
608000
CY2016Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
608000
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
598000

Files In Submission

Name View Source Status
0001564590-17-010224-index-headers.html Edgar Link pending
0001564590-17-010224-index.html Edgar Link pending
0001564590-17-010224.txt Edgar Link pending
0001564590-17-010224-xbrl.zip Edgar Link pending
enta-10q_20170331.htm Edgar Link pending
enta-20170331.xml Edgar Link completed
enta-20170331.xsd Edgar Link pending
enta-20170331_cal.xml Edgar Link unprocessable
enta-20170331_def.xml Edgar Link unprocessable
enta-20170331_lab.xml Edgar Link unprocessable
enta-20170331_pre.xml Edgar Link unprocessable
enta-ex311_7.htm Edgar Link pending
enta-ex312_8.htm Edgar Link pending
enta-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g20170510155132657615.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending